KIORA PHARMACEUTICALS INC (KPRX) — SEC Financial Statements & Analysis

KIORA PHARMACEUTICALS INC (KPRX) is a pharmaceutical preparations company, incorporated in DE. KIORA PHARMACEUTICALS INC trades on Nasdaq, OTC as: KPRX, KPHMW. KIORA PHARMACEUTICALS INC (KPRX)'s most recent SEC filing is a Form 10-Q for the period ended 2026-06-30, filed with the SEC on 2026-08-07. Based on that filing, KIORA PHARMACEUTICALS INC carries a market cap of $16.25M, a P/E ratio of -1.48x, a P/B ratio of 0.96x, a P/S ratio of 634.66x, an enterprise value of $9.17M, and an EV/EBITDA multiple of -0.72x. On profitability, it posts an operating margin of -55210.80%, a net margin of -60257.27%, a Return on Equity (ROE) of -56.36%, a Return on Assets (ROA) of -39.43%, and a Return on Invested Capital (ROIC) of -83.11%. Per share, it reports EPS of $-1.78, diluted EPS of $-1.78, free cash flow per share of $-1.39, and a dividend per share of $0.00. Over the trailing year, it posted revenue growth of -100.00% year-over-year, net income growth of -8.31% year-over-year, and EPS growth of -40.79% year-over-year. On the balance sheet, it maintains a current ratio of 8.97x, a quick ratio of 8.49x, working capital of $18.89M, a debt-to-equity ratio of 0.41x, a debt ratio of 0.29, an interest coverage ratio of -26.32x, free cash flow of $-8.61M (TTM), and net debt of $-7.08M. Figures sourced from SEC EDGAR.

Market Cap

$16.25M

P/E TTM

-1.48x

EPS TTM

$-1.78

P/B TTM

0.96x

ROE TTM

-56.36%

ROA TTM

-39.43%

Debt To Equity

0.41x

Free Cash Flow TTM

$-8.61M

Net Revenue TTM Growth 1Y

-100.00%

Data as of 2026-06-30 · Source: SEC EDGAR